Medicus Pharma (NASDAQ:MDCX) announced its financial results for the second quarter of 2026 and reported regulatory and clinical progress for its SkinJect and Teverelix programs. The company raised approximately $40 million through equity and debt financing in the first half of 2026. However, the company disclosed that there are substantial doubts about its ability to continue as a going concern without additional financing. Regarding its pipeline, the SkinJect program received "Study May Proceed" authorization from the U.S. FDA for its registrational study in patients with Gorlin Syndrome. The Teverelix program received Institutional Review Board (IRB) authorization and positive feedback from the FDA to optimize its Phase 2 study in acute urinary retention, and obtained authorization from the UAE Ministry of Health to initiate the PRECISION-E2 Phase 2 study in women with symptomatic endometriosis. The company reported a net loss of $11.7 million, or $0.21 per share, for the second quarter, compared to a net loss of $6.2 million, or $0.43 per share, in the same period last year.